Sava is a London‑based healthtech startup founded in 2019 by Imperial College bioengineers Renato Circi and Rafaël Michali. The company has developed a wearable microsensor that measures biomarkers just beneath the skin in real time. Its first product is a next‑generation continuous glucose monitor (CGM) designed to be pain‑free, affordable, and more comfortable than traditional filament‑based sensors.

In a clinical trial with 50 Type 1 and insulin‑dependent Type 2 diabetes patients at Oxford and Cambridge, the device delivered accurate glucose readings for up to 10 days. This performance is significant, as most microsensors lose accuracy within a few days. The results support regulatory submissions and larger pivotal trials.

Sava’s technology streams data directly to a smartphone, allowing users to monitor health seamlessly. While glucose is the starting point, the platform is modular, meaning it could track other molecules like lactate, ketones, amino acids, cortisol, and alcohol in the future.